Corbus Pharmaceuticals Announces Completion of Enrollment in NIH-Sponsored Phase 2 Study of Lenabasum for Treatment of Systemic Lupus Erythematosus (SLE)
Go back to Corbus Pharmaceuticals Announces Completion of Enrollment in NIH-Sponsored Phase 2 Study of Lenabasum for Treatment of Systemic Lupus Erythematosus (SLE)| (NASDAQ: CRBP) | Delayed: 33.50 -2.04 (5.74%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $35.54 | 52 Week High | $10.78 | |||
| Open | $34.51 | 52 Week Low | $1.01 | |||
| Day High | $35.09 | P/E | N/A | |||
| Day Low | $32.03 | EPS | $0.00 | |||
| Volume | 142,333 | |||||
